1. Home
  2. AKRO vs COMP Comparison

AKRO vs COMP Comparison

Compare AKRO & COMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • COMP
  • Stock Information
  • Founded
  • AKRO 2017
  • COMP 2012
  • Country
  • AKRO United States
  • COMP United States
  • Employees
  • AKRO N/A
  • COMP N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • COMP EDP Services
  • Sector
  • AKRO Health Care
  • COMP Technology
  • Exchange
  • AKRO Nasdaq
  • COMP Nasdaq
  • Market Cap
  • AKRO 3.9B
  • COMP 3.9B
  • IPO Year
  • AKRO 2019
  • COMP 2021
  • Fundamental
  • Price
  • AKRO $49.65
  • COMP $5.92
  • Analyst Decision
  • AKRO Strong Buy
  • COMP Buy
  • Analyst Count
  • AKRO 8
  • COMP 6
  • Target Price
  • AKRO $82.50
  • COMP $10.17
  • AVG Volume (30 Days)
  • AKRO 1.9M
  • COMP 8.7M
  • Earning Date
  • AKRO 05-12-2025
  • COMP 05-08-2025
  • Dividend Yield
  • AKRO N/A
  • COMP N/A
  • EPS Growth
  • AKRO N/A
  • COMP N/A
  • EPS
  • AKRO N/A
  • COMP N/A
  • Revenue
  • AKRO N/A
  • COMP $5,931,200,000.00
  • Revenue This Year
  • AKRO N/A
  • COMP $25.63
  • Revenue Next Year
  • AKRO N/A
  • COMP $13.67
  • P/E Ratio
  • AKRO N/A
  • COMP N/A
  • Revenue Growth
  • AKRO N/A
  • COMP 19.05
  • 52 Week Low
  • AKRO $17.86
  • COMP $3.34
  • 52 Week High
  • AKRO $58.40
  • COMP $10.25
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 63.34
  • COMP 33.44
  • Support Level
  • AKRO $44.94
  • COMP $5.66
  • Resistance Level
  • AKRO $49.29
  • COMP $6.04
  • Average True Range (ATR)
  • AKRO 3.33
  • COMP 0.27
  • MACD
  • AKRO 0.67
  • COMP -0.00
  • Stochastic Oscillator
  • AKRO 86.02
  • COMP 28.42

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About COMP Compass Inc.

Compass Inc provides an end-to-end platform that empowers residential real estate agents to deliver exceptional service to seller and buyer clients. The platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service and other critical functionality, all custom-built for the real estate industry and enabling core brokerage services. Business operations are conducted in the United States and earn revenue domestically.

Share on Social Networks: